Allergy Partners PA — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$42,052	1
2024	Research	$123,888	1
2023	Research	$71,567	9
2022	Research	$141,898	9
2021	Research	$74,410	4
2020	Research	$110,174	6
2019	Research	$119,555	12

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $566,712 15 payments
Eli Lilly and Company $42,052 1 payment
Novartis Pharmaceuticals Corporation $39,721 5 payments
Regeneron Pharmaceuticals, Inc. $20,940 14 payments
Shire North American Group Inc $9,000 4 payments
GlaxoSmithKline, LLC. $5,118 3 payments

Studies the money was for Research payments · program years 2019–2025

The CHRONICLE Study is a multi center non interventional prospective cohort study of adults with severe asthma who do not achieve control with high dose inhaled corticosteroid ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibody therapy $147,197 4 payments
A Cross Sectional Observational Primary Data Collection Study to Assess the Validity of the US Pediatric Asthma Impairment and Risk Questionnaire AIRQ as a Tool that Identifies Pediatric Patients with Current Uncontrolled Asthma and at Risk for Future Adverse Outcomes $123,888 1 payment
The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod $117,174 3 payments
Implementation of the US PRECISION AIRQT Asthma Checklist and Educational Resources PRECISION Program into Clinical Practice Using Telehealth and In Person Platforms $75,350 1 payment
A Cross-Sectional and Longitudinal Observational Primary Data Collection Study to Assess the Validity of the US Asthma Impairment and Risk Questionnaire (AIRQ) as a Tool that Identifies Patients with Asthma at Risk for Adverse Outcomes from Uncontrolled Asthma $62,600 4 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ Ly3650150 in Adult Participants With Perennial Allergic Rhinitis $42,052 1 payment
A Two Treatment Epoch Randomized Placebo Controlled Multi Centered Parallel Group Study to Assess the Safety of Qaw039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma $33,195 2 payments
An Observational Primary Data Collection Study to Assess the Feasibility of Implementing the US Asthma Risk and Impairment Screener and Evaluation Navigator in Clinical Practice $25,000 1 payment
A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients With Allergic Rhinitis Who Live With a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies During Natural Cat Exposure in the Home $20,940 14 payments
study determine the preferences of patients with asthma or asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome ACOS, and caregivers of non-adult patients with asthma, for rescue and maintenance inhaler attributes EVA-25131-00. $15,503 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.